$Compugen (CGEN.US)$ Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology NEWS PROVIDED BY Compugen Ltd. Feb 26, 2025, 07:00 ET Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulation Leveraging Compugen's computational analytical tools un...
$Compugen (CGEN.US)$ Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors Wednesday, 8th January at 7:00 am • New approach to harness cytokine biology to treat cancer patients advances to the clinic • First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc. • Phase 1 dose escalation and dose expansion trial...
$ABVC BioPharma (ABVC.US)$- Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024. $Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
Report
AddiBee0925
:
Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Steve养老账户
:
I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
$Compugen (CGEN.US)$ Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment. The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
Compugen Stock Forum
How Compugen's AI Platform Partnership Could Revolutionize Cancer Immunotherapy Discovery
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
NEWS PROVIDED BY
Compugen Ltd.
Feb 26, 2025, 07:00 ET
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulation
Leveraging Compugen's computational analytical tools un...
Major Breakthrough: AstraZeneca's New Weapon Against Early-Stage Lung Cancer Enters Final Testing
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Wednesday, 8th January at 7:00 am
• New approach to harness cytokine biology to treat cancer patients advances to the clinic
• First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc.
• Phase 1 dose escalation and dose expansion trial...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
No comment yet